Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit
Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met their primary PFS/OS objectives.



















